Simultaneously, the updated ACMG guideline highlights that PALB2 variants confer breast and ovarian cancer risks comparable to BRCA1/2 and recommends reporting these variants as secondary findings in clinical exome and genome sequencing (Miller et al., 2021). This evidence concerns the gene BRCA1 and ovarian cancer.